Revvity announced the launch of Signals BioDesign, a cloud‑native molecular cloning platform, on April 9, 2026. The new solution expands the company’s Signals Software suite and integrates with its Signals One data‑management platform.
Signals BioDesign supports multiple cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation. It can handle high‑throughput combinatorial cloning for up to 1,000 constructs, positioning it to serve biotech and pharma R&D teams working on antibody, cell, and gene therapies.
The platform will be showcased at the Bio‑IT World Conference & Expo in Boston, May 19‑21, 2026, where Revvity will demonstrate its cloud‑native architecture and AI‑ready data infrastructure. Kevin Willoe, president of Revvity Signals Software, said the solution addresses a critical need for molecular biology teams developing next‑generation therapeutics and empowers researchers with enterprise‑ready collaboration without the complexity of legacy systems.
Revvity’s recent financial performance underscores the company’s capacity to invest in new technology. In Q4 2025, Revvity reported revenue of $772 million, up 6 % year‑over‑year, and an adjusted EPS of $1.70, beating estimates of $1.55. The results reflected strong demand across the company’s life‑sciences and diagnostics segments and disciplined cost management.
The Signals Software portfolio, which also includes Signals Notebook and Signals Xynthetica, is positioned to capture growing demand for cloud‑native, AI‑driven R&D tools. By integrating Signals BioDesign with Signals One, Revvity offers a seamless workflow from design to data management, aligning with industry trends toward scalable, collaborative platforms that accelerate drug discovery.
The launch signals Revvity’s continued focus on expanding its cloud‑native solutions for the life‑sciences sector, reinforcing its strategy to support the development of antibody, cell, and gene therapies. The move is expected to strengthen the company’s competitive position and provide a new revenue stream as the market for advanced therapeutics expands.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.